Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 12, 2009, Pages 4665-4670

  Pazgier, Marzena ^a   Liu, Min ^a,b   Zou, Guozhang ^a   Yuan, Weirong ^a   Li, Changqing ^a   Li, Chong ^a   Li, Jing ^a   Monbo, Juahdi ^a   Zella, Davide ^a   Tarasov, Sergey G ^c   Lu, Wuyuan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE LIBRARY; PROLINE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; THREONYLSERYLPHENYLALANYLALANYLGLUTAMYLTYROSYLTRYPTOPHYL ASPARAGINYLLEUCYLLEUCYLSERYLPROLINE; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PEPTIDE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DETERMINATION; DRUG RECEPTOR BINDING; HYDROGEN BOND; INHIBITION KINETICS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63849271797     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900947106     Document Type: Article

References (32)

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
2. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283.
3. Vousden KH, Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2:594-604.
4. Kirsch DG, Kastan MB (1998) Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 16:3158-3168.
5. Xue W, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656-660.
6. Ventura A, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-665.
7. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127:1323-1334.
8. Toledo F, Wahl GM (2006) Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923.
9. Marine JC, Dyer MA, Jochemsen AG (2007) MDMX: From bench to bedside. J Cell Sci120:371-378.
10. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
11. Jackson MW, Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20:1001-1007.
12. Shvarts A, et al. (1996) MDMX: A novel p53-binding protein with some functional properties of MDM2 EMBO J 15:5349-5357.
13. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303.
14. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
15. Toledo F, et al. (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9:273-285.
16. Francoz S, et al. (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103:3232-3237.
17. Pan Y, Chen J (2003) MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 23:5113-5121.
18. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBOJ 23:1547-1556.
19. de Graaf P, et al. (2003) Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2 J Biol Chem 278:38315-38324.
20. Kawai H, et al. (2003) DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278:45946-45953.
21. Murray JK, Gellman SH (2007) Targeting protein-protein interactions: Lessons from p53/MDM2. Biopolymers 88:657-686.
22. Shangary S, et al. (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105:3933-3938.
23. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303:844-848.
24. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810-8817.
25. Kussie PH, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
26. Sakurai K, Schubert C, Kahne D (2006) Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2 J Am Chem Soc 128:11000-11001.
27. Grasberger BL, et al. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48:909-912.
28. Fasan R, et al. (2006) Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembio- chem 7:515-526.
29. Popowicz GM, et al. (2007) Molecular Basis for the Inhibition of p53 by Mdmx Cell Cycle 6.
30. Lai Z, Auger KR, Manubay CM, Copeland RA (2000) Thermodynamics of p53 binding to hdm2(1-126): Effects of phosphorylation and p53 peptide length. Arch Biochem Biophys 381:278-284.
31. Schon O, et al. (2002) Molecular mechanism of the interaction between MDM2 and p53 J Mol Biol 323:491-501.
32. Bottger A, et al. (1997) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269:744-756.